Open access
Jul 2026
Real-world treatment patterns and outcomes of chemo-immunotherapy with or without radiotherapy in extensive-stage small cell lung cancer: the durvalumab expanded access cohort
In this multinational real-world cohort, outcomes with first-line chemo-immunotherapy were consistent with CASPIAN trial and the addition of cRT or sRT appeared feasible, safe, and associated with clinically meaningful survival improvements.
U. Janžič, W. Shalata, M. Unk et al.
· Frontiers in Oncology · 0 citations